Allogeneic Stem Cell Transplantation In Paroxysmal Nocturnal Hemoglobinuria

Background In the era of eculizumab, identifying patients with paroxysmal nocturnal hemoglobinuria who may benefit from allogeneic stem cell transplantation is challenging. Design and Methods We describe the characteristics and overall survival of 211 patients transplanted for paroxysmal nocturnal hemoglobinuria in 83 EBMT centers from 1978 to 2007. Next, we conducted a comparison with a cohort of 402 non-transplanted patients with paroxysmal nocturnal hemoglobinuria diagnosed between 1950 and 2005 in 92 French centers. We compared the occurrence of complications (i.e. thromboembolism and aplastic anemia) using either an individual or a stratum- matching procedure. Results After a median follow-up of 5 years, the 5-year overall survival rate ± standard error (%) was 68±3 in the transplanted group (54±7 in the case of thromboembolism, 69±5 in the case of aplastic anemia without thromboembolism and 86±6 in the case of recurrent hemolytic anemia without thromboembolism or aplastic anemia). Only thromboembolism as the indication for transplantation was associated with worse outcome (P=0.03). We identified 24 pairs of transplanted and non-transplanted patients with thromboembolism for the matched comparison, with worse overall survival for the transplanted patients (hazard ratio=10.0; 95% confidence interval, 1.3-78.1; P=0.007). This was confirmed by the global matching procedure (P=0.03). As regards aplastic anemia without thromboembolism, 30 pairs were identified for the matched comparison. It was not observed that transplanted patients had a significantly worse overall survival (hazard ratio=4.0; 95% confidence interval, 0.9-18.9; P=0.06). A global matching procedure was not feasible. Conclusions Allogeneic stem cell transplantation is probably not a suitable treatment option for life-threatening thromboembolism in paroxysmal nocturnal hemoglobinuria. ©2012 Ferrata Storti Foundation.971116661673Parker, C., Omine, M., Richards, S., Nishimura, J., Bessler, M., Ware, R., Diagnosis and management of paroxysmal nocturnal hemoglobinuria (2005) Blood, 106 (12), pp. 3699-3709Dameshek, W., Riddle: What do aplastic anemia, paroxysmal nocturnal hemoglobinuria (PNH) and "hypoplastic" leukemia have in common? (1967) Blood, 30 (2), pp. 251-254Socie, G., Mary, J.Y., de Gramont, A., Rio, B., Leporrier, M., Rose, C., Paroxysmal nocturnal haemoglobinuria: Long-term followup and prognostic factors. French Society of Haematology (1996) Lancet, 348 (9027), pp. 573-577Peffault de Latour, R., Mary, J.Y., Salanoubat, C., Terriou, L., Etienne, G., Mohty, M., Paroxysmal nocturnal hemoglobinuria: Natural history of disease subcategories (2008) Blood, 112 (8), pp. 3099-3106Hillmen, P., Hall, C., Marsh, J.C., Elebute, M., Bombara, M.P., Petro, B.E., Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria (2004) N Engl J Med, 350 (6), pp. 552-559Hillmen, P., Young, N.S., Schubert, J., Brodsky, R.A., Socie, G., Muus, P., The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria (2006) N Engl J Med, 355 (12), pp. 1233-1243Helley, D., de Latour, R.P., Porcher, R., Rodrigues, C.A., Galy-Fauroux, I., Matheron, J., Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab (2010) Haematologica, 95 (4), pp. 574-581Hillmen, P., Muus, P., Duhrsen, U., Risitano, A.M., Schubert, J., Luzzatto, L., Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria (2007) Blood, 110 (12), pp. 4123-4128Kelly, R.J., Hill, A., Arnold, L.M., Brooksbank, G.L., Richards, S.J., Cullen, M., Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: Sustained efficacy and improved survival (2011) Blood, 117 (25), pp. 6786-6792Young, N.S., Scheinberg, P., Calado, R.T., Aplastic anemia (2008) Curr Opin Hematol, 15 (3), pp. 162-168Takahashi, Y., McCoy Jr., J.P., Carvallo, C., Rivera, C., Igarashi, T., Srinivasan, R., In vitro and in vivo evidence of PNH cell sensitivity to immune attack after nonmyeloablative allogeneic hematopoietic cell transplantation (2004) Blood, 103 (4), pp. 1383-1390Storb, R., Evans, R.S., Thomas, E.D., Buckner, C.D., Clift, R.A., Fefer, A., Paroxysmal nocturnal haemoglobinuria and refractory marrow failure treated by marrow transplantation (1973) Br J Haematol, 24 (6), pp. 743-750Antin, J.H., Ginsburg, D., Smith, B.R., Nathan, D.G., Orkin, S.H., Rappeport, J.M., Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria: Eradication of the PNH clone and documentation of complete lymphohematopoietic engraftment (1985) Blood, 66 (6), pp. 1247-1250Bemba, M., Guardiola, P., Garderet, L., Devergie, A., Ribaud, P., Esperou, H., Bone marrow transplantation for paroxysmal nocturnal haemoglobinuria (1999) Br J Haematol, 105 (2), pp. 366-368Endo, M., Beatty, P.G., Vreeke, T.M., Wittwer, C.T., Singh, S.P., Parker, C.J., Syngeneic bone marrow transplantation without conditioning in a patient with paroxysmal nocturnal hemoglobinuria: In vivo evidence that the mutant stem cells have a survival advantage (1996) Blood, 88 (2), pp. 742-750Fefer, A., Freeman, H., Storb, R., Hill, J., Singer, J., Edwards, A., Paroxysmal nocturnal hemoglobinuria and marrow failure treated by infusion of marrow from an identical twin (1976) Ann Intern Med, 84 (6), pp. 692-695Hegenbart, U., Niederwieser, D., Forman, S., Holler, E., Leiblein, S., Johnston, L., Hematopoietic cell transplantation from related and unrelated donors after minimal conditioning as a curative treatment modality for severe paroxysmal nocturnal hemoglobinuria (2003) Biol Blood Marrow Transplant, 9 (11), pp. 689-697Lee, J.L., Lee, J.H., Lee, J.H., Choi, S.J., Kim, S., Seol, M., Allogeneic hematopoietic cell transplantation for paroxysmal nocturnal hemoglobinuria (2003) Eur J Haematol, 71 (2), pp. 114-118Raiola, A.M., Van Lint, M.T., Lamparelli, T., Gualandi, F., Benvenuto, F., Figari, O., Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria (2000) Haematologica, 85 (1), pp. 59-62Suenaga, K., Kanda, Y., Niiya, H., Nakai, K., Saito, T., Saito, A., Successful application of nonmyeloablative transplantation for paroxysmal nocturnal hemoglobinuria (2001) Exp Hematol, 29 (5), pp. 639-642Szer, J., Deeg, H.J., Witherspoon, R.P., Fefer, A., Buckner, C.D., Thomas, E.D., Long-term survival after marrow transplantation for paroxysmal nocturnal hemoglobinuria with aplastic anemia (1984) Ann Intern Med, 101 (2), pp. 193-195Matos-Fernandez, N.A., Abou Mourad, Y.R., Caceres, W., Kharfan-Dabaja, M.A., Current status of allogeneic hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria (2009) Biol Blood Marrow Transplant, 15 (6), pp. 656-661Saso, R., Marsh, J., Cevreska, L., Szer, J., Gale, R.P., Rowlings, P.A., Bone marrow transplants for paroxysmal nocturnal haemoglobinuria (1999) Br J Haematol, 104 (2), pp. 392-396Rosse, W.F., Dr Ham's test revisited (1991) Blood, 78 (3), pp. 547-550Hall, S.E., Rosse, W.F., The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria (1996) Blood, 87 (12), pp. 5332-5340Przepiorka, D., Weisdorf, D., Martin, P., Klingemann, H.G., Beatty, P., Hows, J., 1994 Consensus Conference on Acute GVHD Grading (1995) Bone Marrow Transplant, 15 (6), pp. 825-828Fine, J., Gray, R., A proportional hazards models for sub-distribution of a competing risk (1999) J Am Stat Ass, 94, pp. 496-509Kaplan, E.L., Meier, P., Non parametric estimation for incomplete observations (1958) J Am Stat Ass, 53, pp. 457-481Mantel, N., Evaluation of survival data and two new rank order statistics arising in its consideration (1966) Cancer Chemother Rep, 50 (3), pp. 163-170Cox, D.R., Regression models and life-tables (with discussions), series B (1972) J Roy Statist Soc, 34, pp. 184-192Peto, R., Pike, M.C., Armitage, P., Breslow, N.E., Cox, D.R., Howard, S.V., Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples (1977) Br J Cancer, 35 (1), pp. 1-39Byar, D.P., Identification of prognosis factors (1988) Cancer clinical trials, methods and practice, pp. 423-443. , In: Buyse ME, Staquet MJ, Sylvester RJ, eds, Oxford: Oxford Medical PublicationsHillmen, P., Lewis, S.M., Bessler, M., Luzzatto, L., Dacie, J.V., Natural history of paroxysmal nocturnal hemoglobinuria (1995) N Engl J Med, 333 (19), pp. 1253-1258Rosse, W.F., Nishimura, J., Clinical manifestations of paroxysmal nocturnal hemoglobinuria: Present state and future problems (2003) Int J Hematol, 77 (2), pp. 113-120Brodsky, R.A., Young, N.S., Antonioli, E., Risitano, A.M., Schrezenmeier, H., Schubert, J., Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria (2008) Blood, 111 (4), pp. 1840-1847Santarone, S., Bacigalupo, A., Risitano, A.M., Tagliaferri, E., Di Bartolomeo, E., Iori, A.P., Hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: Long-term results of a retrospective study on behalf of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) (2010) Haematologica, 95 (6), pp. 983-988Maury, S., Balere-Appert, M.L., Chir, Z., Boiron, J.M., Galambrun, C., Yakouben, K., Unrelated stem cell transplantation for severe acquired aplastic anemia: Improved outcome in the era of high-resolution HLA matching between donor and recipient (2007) Haematologica, 92 (5), pp. 589-596Rosenbaum, P.R., The central role of the propensity score in observational studies for causal effects (1983) Biometrika, 70, pp. 41-55Dunn, D.E., Tanawattanacharoen, P., Boccuni, P., Nagakura, S., Green, S.W., Kirby, M.R., Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes (1999) Ann Intern Med, 131 (6), pp. 401-408Marsh, J.C., Ball, S.E., Cavenagh, J., Darbyshire, P., Dokal, I., Gordon-Smith, E.C., Guidelines for the diagnosis and management of aplastic anaemia (2009) Br J Haematol, 147 (1), pp. 43-70Kojima, S., Nakao, S., Young, N., Bacigalupo, A., Gerard, G., Hirano, N., The Third Consensus Conference on the treatment of aplastic anemia (2011) Int J Hematol, 93 (6), pp. 832-837Schrezenmeier, H., Passweg, J.R., Marsh, J.C., Bacigalupo, A., Bredeson, C.N., Bullorsky, E., Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia (2007) Blood, 110 (4), pp. 1397-1400Eapen, M., Le Rademacher, J., Antin, J.H., Champlin, R.E., Carreras, J., Fay, J., Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia (2011) Blood, 118 (9), pp. 2618-262